

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

May 9, 2016  
Date of Report (Date of earliest event reported)

**Flex Pharma, Inc.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other jurisdiction of incorporation)	<b>001-36812</b> (Commission File Number)	<b>46-5087339</b> (IRS Employer Identification No.)
<b>800 Boylston Street, 24th Floor Boston, MA</b> (Address of principal executive offices)		<b>02199</b> (Zip Code)

Registrant's telephone number, including area code: **(617) 874-1821**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 1.01 Entry into a Material Definitive Agreement.**

On May 9, 2016, Flex Innovation Group LLC ("Flex Innovation"), a wholly owned subsidiary of Flex Pharma, Inc. (the "Company"), entered into a Supply Agreement (the "Supply Agreement") with Trilogy Essential Ingredients Inc. ("Trilogy") pursuant to which Trilogy agreed to manufacture and supply the Company with certain ingredients included in the Company's consumer product.

Under the terms of the Supply Agreement, Flex Innovation will submit purchase orders to Trilogy, which will manufacture and supply the ingredients in compliance with the specifications agreed upon by the parties. Pricing for the ingredients will be based on a per pound price for the ingredients purchased by Flex Innovation and is subject to adjustment as provided in the Supply Agreement. Flex Innovation has also agreed that Trilogy will be the sole U.S. provider of certain ingredients used in the consumer product for a two-year period. The exclusivity provided to Trilogy in the Supply Agreement will terminate upon the occurrence of certain events.

The initial term of the Supply Agreement is for two years and will automatically renew for additional one-year periods, unless either party gives prior written notice to the other party. Either party may terminate the Supply Agreement with written notice of a material breach of the Supply Agreement by the other party, if such breach has not been cured within a defined period of receiving such notice. In addition, Flex Innovation may terminate the Supply Agreement at any time following written notice to Trilogy. The Supply Agreement provides Flex Innovation with certain last time buy rights prior to any expiration of the Supply Agreement.

The Supply Agreement also includes customary provisions relating to delivery of products, acceptance and rejection procedures, quality control, intellectual property, regulatory matters, warranties, indemnification, confidentiality and insurance.

The foregoing description of the Supply Agreement is only a summary and is qualified in its entirety by reference to the Supply Agreement. The Company intends to file a copy of the Supply Agreement as an exhibit to its Quarterly Report on Form 10-Q for its quarter ending June 30, 2016, portions of which will be subject to a FOIA Confidential Treatment Request to the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

In anticipation of the launch of the Company's consumer product to prevent and treat exercise associated muscle cramps, Katharine Lindemann, the Company's Chief Operating Officer, has assumed responsibility for managing the operations of the Company's consumer group. Ms. Lindemann joined the Company in August 2015 and previously served as the Chief Operating Officer of DAVIDsTea Inc. and also spent 19 years at Starbucks Corporation in a variety of roles, most recently, as Senior Vice President, Starbucks Foodservice. Marina Hahn will continue in her role as the Company's President, Consumer. In this role, Ms. Hahn will be providing strategic and marketing guidance relating to the Company's consumer product.

On May 9, 2016, the Company, Flex Innovation and Ms. Hahn entered into an amendment to Ms. Hahn's offer letter, providing for, among other things, the acceleration of a portion of the stock options previously granted to Ms. Hahn in the event she is terminated by the Company prior to December 31, 2016 without Cause, as such term is defined in Ms. Hahn's offer letter.

The foregoing summary of the amendment to Ms. Hahn's offer letter is qualified in its entirety by the full text of the amendment, which is filed herewith as Exhibit 10.1 and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
10.1	Amendment to Offer Letter, dated May 9, 2016, by and between Flex Innovation, the Company and Marina Hahn

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Flex Pharma, Inc.**

Dated: May 13, 2016

By: /s/ Robert Hadfield

Robert Hadfield

General Counsel and Secretary

---

## INDEX TO EXHIBITS

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
10.1	Amendment to Offer Letter, dated May 9, 2016, by and between Flex Innovation, the Company and Marina Hahn



May 9, 2016

Marina Hahn  
1155 Park Avenue  
New York, NY 10128

Dear Marina:

This letter agreement sets out the terms of your continued employment with Flex Innovation Group LLC (the “Company”) and amends that certain offer letter between you and Flex Pharma, Inc. (“Flex Pharma”) dated September 4, 2014, as amended on May 27, 2015 and July 20, 2015 (as amended, the “Offer Letter”), which Offer Letter has been assigned by Flex Pharma to the Company. Capitalized terms used herein not otherwise defined shall have the meanings ascribed to them in the Offer Letter.

The parties acknowledge and agree that pursuant to that certain Stock Option Grant Notice dated November 10, 2014, including the Option Agreement attached thereto (the “Option Agreement”), and Flex Pharma’s 2014 Equity Incentive Plan (the “Plan”), you were granted an option (the “Option”) by Flex Pharma to purchase 248,855 shares of the Company’s Common Stock, which shares vest over a four year period, subject to your continued employment with the Company. The parties hereby agree that if the Company terminates your employment without Cause prior to December 31, 2016, then effective as of the date of such termination, an additional number of shares of Flex Pharma’s Common Stock subject to the Option shall vest and become exercisable equal to (i) the number of months remaining in calendar year 2016 as of the employment termination date and including the month of termination, *multiplied by* (ii) 5,185 shares. Such additional number of vested shares shall be exercisable in accordance with the terms of the Option Agreement and the Plan. Such additional vesting shall be conditioned upon the Company’s receipt of an effective, general release of claims in favor of the Company in a form acceptable to the Company within 30 days following such termination date.

The Company hereby agrees to waive its right to terminate your employment for Cause for any action, of which the Company is aware, taken by you prior to the date hereof in the conduct of your employment. You hereby agree to waive your right to terminate your employment with the Company for Good Reason for any action taken by the Company prior to the date hereof.

All other terms and provisions of the Offer Letter and the Option Agreement not expressly modified hereby shall remain in full force and effect. This letter may not be modified or amended except by a written agreement signed by the Company and you.

---

Sincerely,  
Flex Innovation Group LLC

/s/ Robert Hadfield  
Name: Robert Hadfield  
Title: General Counsel

AGREED:

/s/ Marina Hahn  
Marina Hahn

Flex Pharma, Inc.

/s/ Robert Hadfield  
Name: Robert Hadfield  
Title: General Counsel